2024-09-01 - Analysis Report
## AMGN Stock Analysis

**Company:** Amgen (AMGN) is a leading biotechnology company developing and manufacturing human therapeutics.

**1. Performance Relative to S&P 500 (VOO):**

* **Cumulative Return:** AMGN: 58.57%, VOO: 89.66%
* **Relative Underperformance:** -18.75% (Relative Divergence: 45.21%)
* **Interpretation:** AMGN has underperformed the S&P 500 by approximately 18.75% over the period analyzed. Its current relative divergence suggests that it is performing within the lower 45% range of its historical performance relative to the S&P 500.

**2. Recent Price Movements:**

* **Closing Price:** $333.83
* **5-day Moving Average:** $329.61
* **20-day Moving Average:** $325.69
* **60-day Moving Average:** $321.37
* **Interpretation:** The stock price is currently above its 5, 20, and 60-day moving averages, indicating a potential upward trend.

**3. Technical Indicators:**

* **RSI:** 68.97
* **PPO:** 0.17
* **Delta_Previous_Relative_Divergence:** -11.23
* **Interpretation:**  The RSI suggests the stock is in overbought territory, potentially indicating a near-term correction. The PPO is positive, indicating bullish momentum. The negative Delta_Previous_Relative_Divergence suggests a recent slowdown in relative performance compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date        | EPS    | Revenue         |
|-------------|--------|-----------------|
| 2024-08-07 | 1.39   | $8.39 Billion    |
| 2024-05-03 | -0.21  | $7.45 Billion    |
| 2023-10-31 | 3.23   | $6.90 Billion    |
| 2023-08-04 | 2.58   | $6.99 Billion    |
| 2024-08-07 | 2.58   | $6.99 Billion    |

**Interpretation:** The most recent earnings report (2024-08-07) showed a significant jump in EPS and revenue compared to the previous quarter. The company has shown consistent revenue growth over the past year. While the most recent earnings beat analyst expectations, the overall earnings trend and future outlook remain uncertain. 

**5.  Overall Analysis:**

* AMGN has underperformed the S&P 500 in the period analyzed, but its current price is above its key moving averages, suggesting potential upside. 
* The stock is currently considered overbought based on the RSI, but the PPO indicates positive momentum.
* The recent earnings report shows strong growth in both EPS and revenue, suggesting potential for continued growth. 
* However, the future outlook remains uncertain, and further analysis is required to understand the company's long-term prospects.

**6. Recommendation:**

AMGN is a large-cap company with a long history of success in the biotechnology sector. While the stock has underperformed the market recently, its recent earnings beat and strong revenue growth provide reason for optimism. Further research, including a review of analyst recommendations and an assessment of potential risks, is needed to determine whether AMGN is a good investment at its current price. 
